Celiac Disease Cd Epidemiology Forecast

DelveInsight's 'Celiac Disease (CD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease (CD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Celiac Disease (CD) Understanding

The DelveInsight Celiac Disease (CD) epidemiology report gives a thorough understanding of the Celiac Disease (CD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Celiac Disease (CD) in the US, Europe, and Japan. The report covers the detailed information of the Celiac Disease (CD) epidemiology scenario in seven major countries (US, EU5, and Japan).


Celiac Disease (CD) Epidemiology Perspective by DelveInsight

The Celiac Disease (CD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Celiac Disease (CD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Celiac Disease (CD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Celiac Disease (CD) Detailed Epidemiology Segmentation

The Celiac Disease (CD) epidemiology covered in the report provides historical as well as forecasted Celiac Disease (CD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Celiac Disease (CD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Celiac Disease (CD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Celiac Disease (CD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Celiac Disease (CD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Celiac Disease (CD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Celiac Disease (CD)
  • The report provides the segmentation of the Celiac Disease (CD) epidemiology


Report Highlights

  • 11-Year Forecast of Celiac Disease (CD) epidemiology
  • 7MM Coverage
  • Total Cases of Celiac Disease (CD)
  • Total Cases of Celiac Disease (CD) according to segmentation
  • Diagnosed cases of Celiac Disease (CD)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Celiac Disease (CD)?
  • What are the key findings pertaining to the Celiac Disease (CD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Celiac Disease (CD) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Celiac Disease (CD)?
  • What are the currently available treatments of Celiac Disease (CD)?


Reasons to buy

  • The Celiac Disease (CD) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Celiac Disease (CD) market
  • Quantify patient populations in the global Celiac Disease (CD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Celiac Disease (CD) therapeutics in each of the markets covered
  • Understand the magnitude of Celiac Disease (CD) population by its epidemiology
  • The Celiac Disease (CD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Celiac Disease (CD)

3. Celiac Disease (CD): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Celiac Disease (CD) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Celiac Disease (CD) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Celiac Disease (CD) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Celiac Disease (CD) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Celiac Disease (CD) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Celiac Disease (CD) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Celiac Disease (CD) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Celiac Disease (CD) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Celiac Disease (CD) Treatment and Management

6.2. Celiac Disease (CD) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Celiac Disease (CD) Epidemiology in 7MM (2017-2030)

Table 2 Celiac Disease (CD) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Celiac Disease (CD) Epidemiology in the United States (2017-2030)

Table 4 Celiac Disease (CD) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Celiac Disease (CD) Epidemiology in Germany (2017-2030)

Table 6 Celiac Disease (CD) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Celiac Disease (CD) Epidemiology in France (2017-2030)

Table 8 Celiac Disease (CD) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Celiac Disease (CD) Epidemiology in Italy (2017-2030)

Table 10 Celiac Disease (CD) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Celiac Disease (CD) Epidemiology in Spain (2017-2030)

Table 12 Celiac Disease (CD) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Celiac Disease (CD) Epidemiology in the United Kingdom (2017-2030)

Table 14 Celiac Disease (CD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Celiac Disease (CD) Epidemiology in Japan (2017-2030)

Table 16 Celiac Disease (CD) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Celiac Disease (CD) Epidemiology in 7MM (2017-2030)

Figure 2 Celiac Disease (CD) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Celiac Disease (CD) Epidemiology in the United States (2017-2030)

Figure 4 Celiac Disease (CD) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Celiac Disease (CD) Epidemiology in Germany (2017-2030)

Figure 6 Celiac Disease (CD) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Celiac Disease (CD) Epidemiology in France (2017-2030)

Figure 8 Celiac Disease (CD) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Celiac Disease (CD) Epidemiology in Italy (2017-2030)

Figure 10 Celiac Disease (CD) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Celiac Disease (CD) Epidemiology in Spain (2017-2030)

Figure 12 Celiac Disease (CD) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Celiac Disease (CD) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Celiac Disease (CD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Celiac Disease (CD) Epidemiology in Japan (2017-2030)

Figure 16 Celiac Disease (CD) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Celiac Disease (CD) Epidemiology
  • Celiac Disease (CD)
  • Celiac Disease (CD) Pipeline
  • Celiac Disease (CD) Companies
  • Celiac Disease (CD) prevalent popu...
  • Celiac Disease (CD) incident popul...
  • Celiac Disease (CD) patients diagn...
  • Celiac Disease (CD) treatment algo...

Forward to Friend

Need A Quote